Skip to main content

Advertisement

Table 1 Baseline characteristics of 174 adults receiving therapy for hyperprolactinemia

From: Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

CharacteristicOverall
(n = 174)
Type of Hyperprolactinemia Therapy
Bromocriptine
(N = 63)
Cabergoline
(N = 62)
Cabergoline and Bromocriptine
(N = 49)
Age, years
 Median (IQR)47.3 (39.8, 56.8)48.2 (42.3, 59.3)46.7 (39.4, 57.7)48.2 (36.7, 54.6)
 Mean ± SD48.9 ± 12.650.3 ± 12.648.7 ± 13.147.2 ± 12.1
 Age Group, n (%)   p = 0.0743
  21–40 years50 (28.7)13 (20.6)19 (30.7)18 (36.7)
  41–60 years90 (51.7)35 (55.6)32 (51.6)23 (46.9)
   > 60 years34 (19.5)15 (23.8)11 (17.7)8 (16.3)
Women (%)110 (63.2)43 (68.3)29 (46.8) *38 (77.6)
Race, n (%)   
 White / European75 (43.1)29 (46.0)28 (45.2)18 (36.7)
 African American / Black33 (19.0)5 (7.9)9 (14.5)19 (38.8)
 Hispanic / Latino26 (14.9)13 (20.6)10 (16.1)3 (6.1)
 Asian32 (18.4)11 (17.5)12 (19.4)9 (18.4)
 Native American2 (1.2)1 (1.6)1 (1.6)0
 Other6 (3.5)4 (6.4)2 (3.2)0
Body-Mass Index, kg/m2, n (%)
  < 207 (4.1)1 (3.2)1 (1.6)5 (8.2)
 20–24.946 (26.4)16 (25.4)17 (27.4)13 (26.5)
 25–29.941 (23.6)15 (23.8)21 (33.9)5 (10.2)
  ≥ 3079 (45.4)29 (46.0)23 (37.1)27 (55.1)
 Unknown1 (0.6)1 (1.6)00
Smoking History
 Currently smoking, n (%)9 (5.2)3 (4.8)3 (4.8)3 (6.1)
 Cigarettes per day, median (IQR)b18.0 (6.0, 20.0)18.0 (2.5, 20.0)20.0 (20.0, 20.0)6.0 (1.0, 10.0)
 Years of smoking, median (IQR)c15.0 (6.0, 30.0)6.0 (3.0, 15.0)30.0 (20.0, 32.0)15.0 (1.0, 43.0)
 Previously smoked, n (%)54 (31.0)22 (34.9)21 (33.9)11 (22.5)
Medication History
 Filled prescriptions, n (%)d160 (92.0)60 (95.2)54 (87.1)46 (93.9)
 Cabergoline, median (IQR)
  Weekly Dose prescribed (mg)1.0 (0.5, 1.0)n/a0.75 (0.5, 1.0)1.0 (0.5, 1.0) ‡ a
  Estimated Cumulative Dose (mg)115.3 (52.2, 259.1)n/a98.0 (56.7, 214.0)147.6 (45.4, 321.0)
  Length of time, in years2.9 (1.6, 5.2)n/a2.8 (1.9, 4.8)3.2 (1.4, 6.1)
  No. of prescriptions filled (per person)15.0 (8.0, 24.0)n/a15.0 (10.0, 20.0)14.0 (6.0, 29.0) *a
 Bromocriptine, median (IQR)
  Daily Dose prescribed (mg)2.5 (2.5, 5.0)2.5 (2.5, 5.0)n/a5.0 (2.5, 7.5)
  Estimated Cumulative Dose (mg)3711.9 (1023.8, 10,026.7)6065.0 (2413.5, 11,630.0)n/a1127.5 (392.5, 4305.0)
  Length of time, in years2.9 (1.1, 7.2)5.5 (2.4, 9.8)n/a1.1 (0.5, 2.5)
  No. of prescriptions filled (per person)14.5 (5.0, 36.0)26.0 (10.0, 44.0)n/a5.0 (2.0, 16.0)
Current Medication Usage (self-reported)
 Cabergoline current user, n (%)96 (55.2)n/a57 (91.9)39 (79.6)
  Length of time (years), median (IQR) e5.0 (2.0, 6.9)n/a4.3 (2.0, 6.4)5.0 (2.1, 8.0)
  No. of days per week, median (IQR) f2.0 (1.0, 2.0)n/a2.0 (1.0, 2.0)2.0 (1.0, 2.0)
  Days per week varies, n (%)g20 (11.5)n/a8 (14.5)11 (22.5)
 Bromocriptine current user, n (%)63 (36.2)57 (90.5)n/a6 (12.2)
  Length of time (years), median (IQR)9.0 (4.5, 15.0)9.0 (4.5, 15.0)n/a9.0 (4.8, 10.0)
  No. of days per week, median (IQR)7.0 (7.0, 7.0)7.0 (7.0, 7.0)n/a7.0 (7.0, 7.0)
  No. of days per week varies, n (%)7 (4.0)5 (7.9)n/a2 (4.1)
  Amount taken varies, n (%)h12 (6.9)11 (17.5)n/a1 (2.0)
Pregnancyn = 110 womenn = 43 womenn = 29 womenn = 38 women
 Stopped taking due to pregnancy, n (%)23 (20.9)10 (23.3)5 (17.2)8 (21.1)
 No. of times pregnant, median (IQR)2.0 (1.0, 2.0)2.0 (1.0, 2.0)1.0 (1.0, 2.0)2.0 (1.0, 3.0)
 Breastfeeding duration, mos, median (IQR)2.0 (0, 4.0)2.0 (0, 5.5)3.0 (2.0, 3.0)1.0 (0.0, 4.3)
Risk Factors
 Migraines
  Treated, n (%)24 (13.8)8 (12.7)7 (11.3)9 (18.4)
 Type of drugs taken, n (%)
  Dihydroergotamine, DHE 450000
  Ergotomone, Ergomar1 (0.6)01 (1.6)0
  Unknown7 (4.0)2 (3.2)3 (4.8)2 (4.1)
 Weight Loss / Appetite Suppressant Drugs
 Taken to Suppress Appetite, n (%)8 (4.6)2 (3.2)2 (3.2)4 (8.2)
 Type of drugs taken, n (%)    
  Phentermine0000
  Dexfenfluramine0000
  Other8 (4.6)2 (3.2)2 (3.2)4 (8.2)
   Unknown / forgot5 (62.5)2 (100.0)03 (75.0)
   Nano Slim Haudia1 (12.5)01 (50.0)0
   GNC BNRN 601 (12.5)001 (25.0)
  Hydroxycut1 (12.5)01 (50.0)0
   None166 (95.4)61 (96.8)58 (93.6)47 (95.9)
 Medical History, n (%)
  Endocarditis0000
  Rheumatic Fever1 (0.6)1 (1.6)00
  Mitral Valve Prolapse2 (1.2)01 (1.6)1 (2.0)
  Heart Failure1 (0.6)1 (1.6)00
  Myocardial Infarction1 (0.6)1 (1.6)00
  High blood pressure23 (13.2)8 (12.9)7 (11.1)8 (16.3)
  1. * P value < 0.05; P value < 0.01; P value < 0.001
  2. a Compares cabergoline to both users
  3. b Mean number of cigarettes smoked per day
  4. c Total number of years of smoking at average number of cigarettes per day
  5. d Number of patients who filled all their prescriptions with Kaiser Permanente pharmacies
  6. e Total years patient has taken drug
  7. f Mean number of days per week patient takes medication
  8. g Number of patients varying the number of days per week medication is taken
  9. h Number of patients whose medication amount taken varies